期刊
CURRENT OPINION IN VIROLOGY
卷 17, 期 -, 页码 45-49出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2016.01.006
关键词
-
类别
资金
- Public Health Agency of Canada (PHAC)
- United States Defense Threat Reduction Agency [HDTRA1-13-C-0018]
- National Institutes of Health [U19AI109762]
- Biomedical Advanced Rekarch and Development Authority [HHSO100201400009C]
With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据